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News
Iowa
Board of Pharmacy
Board Members Reappointed
Iowa Board of Pharmacy members Edward L. Maier, James A. 
Miller, and LaDonna Gratias were reappointed by Governor Terry 
Branstad to additional three-year terms beginning May 1, 2014 and 
ending April 30, 2017. Ed Maier has been re-elected as Board chair-
person and Jim Miller has been re-elected as Board vice chairperson, 
effective May 1, 2014 to April 30, 2015. The Board congratulates 
Ed, Jim, and LaDonna on their reappointments and thanks them for 
their continued public service.
PIC Advisory Committee
The following individuals have agreed to serve on a new Board of 
Pharmacy/Iowa Pharmacy Association advisory committee to review 
and revise pharmacist-in-charge (PIC) responsibilities and Board 
rules related to pharmacy ownership and the duties of pharmacy 
owners: Cheryl Clarke, Drake University, College of Pharmacy and 
Health Sciences, Des Moines, IA; Brian Benson, UnityPoint Health, 
Des Moines; Cory Garvin, Wester Drug, Muscatine, IA; Angie 
Nelson, Hy-Vee, Jefferson, IA; Amanda Rosmann, Walgreens, 
Ankeny, IA; Dave Scofield, Hartig Drug, Dubuque, IA; Mike 
Fuller, Walgreens, Ankeny; and Edward McKenna, Hy-Vee, Storm 
Lake, IA. The committee held its first meeting on May 13, 2014. It 
is anticipated that the committee will make recommendations to the 
Board and the Iowa Pharmacy Association before the end of 2014.
Iowa/NABP Pharmacy Inspection Project 
Results
The Board recently completed a special project in which nearly 
80% of nonresident (out-of-state) pharmacies licensed to do business 
in Iowa were inspected. Between December 1, 2012 and December 
31, 2013, a total of 538 nonresident pharmacies were surveyed with 
the assistance of the field services division of the National Associa-
tion of Boards of Pharmacy® (NABP®). 
The pharmacies that were inspected were located in 42 states. 
The top 10 states were:
 ♦ Florida: 69 pharmacies
 ♦ Illinois: 45 pharmacies
 ♦ Nebraska: 41 pharmacies
 ♦ California: 31 pharmacies
 ♦ Pennsylvania: 30 pharmacies
 ♦ Minnesota: 26 pharmacies
 ♦ Missouri: 22 pharmacies
 ♦ Tennessee: 21 pharmacies
 ♦ Texas: 20 pharmacies
 ♦ Ohio: 20 pharmacies
A total of 263 pharmacies (49%) were found to be engaged in some 
form of compounding. One hundred thirteen pharmacies (21%) were 
found to be doing both sterile and nonsterile compounding. Eighty-
five pharmacies (16%) were doing only nonsterile compounding, 
while 65 pharmacies (12%) were doing only sterile compounding.
Of those pharmacies that were engaging in sterile compounding, 
the following was observed:
 ♦ High-risk preparations by prescription: 93 pharmacies
 ♦ High-risk preparations without a prescription: 40 pharmacies
 ♦ Medium-risk preparations by prescription: 121 pharmacies
 ♦ Medium-risk preparations without a prescription: 24 phar-
macies
 ♦ Low-risk preparations by prescription: 134 pharmacies
 ♦ Low-risk preparations without a prescription: 23 pharmacies
In addition, 158 pharmacies (29%) were found to be performing 
bulk compounding without a prescription in anticipation of receiving 
prescriptions. There were 14 pharmacies that were also licensed as 
a distributor, with internal movement of compounded product from 
the pharmacy to the distributor.
These pharmacies ranged in size from 65 square feet to 163,000 
square feet. The size of their compounding areas ranged from two 
square feet to 1,000 square feet. 
The number of pharmacists per facility ranged from one to 258, 
while the number of pharmacy technicians ranged from one to 668. 
Some facilities dispensed up to 90,000 prescriptions per day. The 
number of prescriptions dispensed to Iowa patients ranged from 
one to 1,285 per day.
Interestingly, 47 of these same pharmacies (8.7%) were also 
inspected by Food and Drug Administration (FDA) during the 
same time period. Twenty-six of those pharmacies (4.8%) received 
a warning letter from FDA.
One hundred nine pharmacies (20%) were found to be operating 
under a waiver granted by their home state board of pharmacy. The 
types of pharmacies inspected included the following:
 ♦ Traditional retail/Community
 ♦ Health Maintenance Organization/Pharmacy Benefit Man-
agement only
 ♦ Institutional (hospital or long-term care)
 ♦ Mail order
 ♦ Central fill/Central processing
 ♦ Internet pharmacy
 ♦ Telepharmacy
The results of these inspections have been reviewed by the Board. 
In some cases, nonresident pharmacies have been issued letters of 
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it as Benadryl and placed a bottle of diphenhydramine in the bag 
for pick-up. Around this same time, the pharmacy went through a 
change in wholesaler and many manufacturers of generic products 
were changed. A few days later, a coworker of the patient picked 
up the medication (along with several others). The technician at 
the point-of-sale told the coworker that many of the manufacturers 
had changed recently and that some of the pills may look different. 
The patient received the diphenhydramine, filled her medication 
box with the capsules, and took diphenhydramine daily for three 
weeks before noticing she was unusually tired. When she brought 
the bottle back to the pharmacy, the error was recognized.
ISMP continues to receive reports of confused drug name 
pairs being involved in errors. ISMP wants to inform its readers 
of these drug name confusions so they may continue evaluating 
what measures they have in place to protect against these possible 
confusions.
Your Help Is Needed With Product Safety Testing. If you are 
a pharmacist, nurse, pharmacy technician, or other health care prac-
titioner who is interested in furthering medication safety and error 
prevention, you can make a difference! Med-ERRS (a subsidiary of 
ISMP) is looking for assistance to help evaluate medication labels, 
drug packaging, and proposed drug names prior to submission 
by pharmaceutical and biotech companies for approval by Food 
and Drug Administration (FDA). The process is fun, simple, and 
easy. A small honorarium is paid. For more information or to sign 
up, visit www.med-errs.com and click on “Become a Reviewer.”
FDA Issues Alert on Acetaminophen Products 
In light of all the recent news alerts and warnings about the use 
of acetaminophen and acetaminophen-containing products, FDA 
issued a recommendation of importance to pharmacists, prescrib-
ers, and patients.
FDA recommends that health care providers consider prescrib-
ing combination drug products that contain 325 mg or less of 
acetaminophen. FDA also recommends that when a pharmacist 
receives a prescription for a combination product with more than 
325 mg of acetaminophen per dosage unit that he or she contacts 
the prescriber to discuss a product with a lower dose of acetamino-
phen. A two-tablet or two-capsule dose may still be prescribed, if 
appropriate. In that case, the total dose of acetaminophen would be 
650 mg (the amount in two 325 mg dosage units). When making 
individual dosing determinations, health care providers should 
always consider the amounts of both the acetaminophen and the 
opioid components in the prescription combination drug product.
FDA, in its MedWatch Safety Alert, reports that, “There are no 
available data to show that taking more than 325 mg of acetamino-
phen per dosage unit provides additional benefit that outweighs 
the added risks for liver injury. Further, limiting the amount of 
acetaminophen per dosage unit will reduce the risk of severe liver 
injury from inadvertent acetaminophen overdose, which can lead 
to liver failure, liver transplant, and death.”
In January 2011, FDA asked manufacturers of prescription 
combination drug products containing acetaminophen to limit 
the amount of acetaminophen to no more than 325 mg in each 
tablet or capsule by January 14, 2014. FDA requested this action 
to protect consumers from the risk of severe liver damage that 
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New USP Webpage Answers Common 
Questions About USP Chapters <795>  
and <797> 
In response to questions concerning United States Pharmaco-
peia-National Formulary (USP-NF) General Chapters <795> and 
<797>, USP has created a new frequently asked questions (FAQs) 
page on its website. The FAQs answer questions related to the Revi-
sion Bulletin for Chapter <795> that was issued on November 22, 
2013, and became official on January 1, 2014. Among other topics, 
the FAQs address common questions regarding beyond-use dating 
and the differences between testing stability with strength (potency) 
or stability-inducing methods. The FAQs can be accessed at www 
.usp.org/support-home/frequently-asked-questions/compounding. 
Question four on the page includes a link to a USP article, “Strength 
and Stability Testing for Compounded Preparations.”
Only You Can Prevent Look-Alike Sound-Alike 
Drug Names 
This column was prepared by the Institute 
for Safe Medication Practices (ISMP). 
ISMP is an independent nonprofit agency 
and federally certified patient safety organization that analyzes 
medication errors, near misses, and potentially hazardous 
conditions as reported by pharmacists and other practitioners. 
ISMP then makes appropriate contacts with companies and 
regulators, gathers expert opinion about prevention measures, and 
publishes its recommendations. To read about the risk reduction 
strategies that you can put into practice today, subscribe to ISMP 
Medication Safety Alert!® Community/Ambulatory Care Edition 
by visiting www.ismp.org. ISMP provides legal protection and 
confidentiality for submitted patient safety data and error reports. 
Help others by reporting actual and potential medication errors to 
the ISMP National Medication Error Reporting Program. Report 
online at www.ismp.org. E-mail: ismpinfo@ismp.org.
VESIcare/Vesanoid Mix-Up. A prescriber’s office sent an 
electronic prescription to the patient’s pharmacy; the prescriber 
intended to prescribe VESIcare® (solifenacin succinate) for 
overactive bladder but inadvertently selected Vesanoid® (treti-
noin), which is used to induce remission of acute promyelocytic 
leukemia. The pharmacy technician entered the prescription for 
generic tretinoin; however, the pharmacy was unable to dispense 
the medication as the patient’s pharmacy benefit manager required 
a prior authorization. The technician faxed a request and the pre-
scriber’s office replied back that VESIcare was intended. Both 
of these products are available in 10 mg solid oral dosage forms, 
increasing the risk of confusion. Investigate strategies (eg, tall 
man letters) to differentiate these products on computer screens. 
Prescribers should include the indication for the drug with the 
prescription. As always, providing patient education, especially 
for new prescriptions, is a good strategy to intercept errors before 
they impact the patient.
Benazepril Confused With Benadryl. A pharmacist reported 
a mix-up between benazepril (Lotensin®) and Benadryl® (diphen-
hydramine). A patient faxed a request to the pharmacy to ask for 
her “benazapryl.” The pharmacist who received the fax interpreted 
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can result from taking too much acetaminophen. More than half 
of manufacturers have voluntarily complied with FDA’s request. 
However, some prescription combination drug products contain-
ing more than 325 mg of acetaminophen per dosage unit remain 
available. In the near future, FDA intends to institute proceedings 
to withdraw approval of prescription combination drug products 
containing more than 325 mg of acetaminophen per dosage unit 
that remain on the market.
Boards of pharmacy have received inquiries from pharmacists 
about remaining stock of the higher dose acetaminophen and what 
procedures should be followed. The FDA recommendation notes 
that pharmacists are advised to contact prescribers and request a 
change in the prescription. If the prescriber is not willing to make 
the change in the prescription, unfortunately, there is no clear cut 
recommendation at this point as to whether to dispense the higher 
dose acetaminophen product. It would appear that the higher dose 
acetaminophen-containing products will be regarded by FDA as 
unapproved and delisted from FDA’s Approved Drug Products 
With Therapeutic Equivalence Evaluations, commonly known as 
the “Orange Book.” Until this occurs, pharmacists must make a 
judgment regarding continuing to dispense the higher dose acet-
aminophen containing products in light of the FDA recommenda-
tion and concern for patient safety. 
Some Rohto Eye Drops Products Recalled
The Mentholatum Company of Orchard Park, NY, has issued a 
voluntary recall of some Rohto® eye drop products due to a manu-
facturing review at the production facility in Vietnam involving 
sterility controls. The recall has been issued at the retail level and 
includes Rohto Arctic, Rohto Ice, Rohto Hydra, Rohto Relief, and 
Rohto Cool eye drops that were manufactured in Vietnam. Products 
made in other facilities are not affected by the recall. To date, there 
has been no evidence indicating the recalled products do not meet 
specifications, according to a press release. 
The recalled products are sold over the counter at pharmacies 
and retail stores throughout the United States, and can be identi-
fied by the words “Made in Vietnam” on the side carton panel 
under the company name and address information as well as on 
the back label of the bottle. Lot numbers for the recalled products 
contain the letter “V.” Distributors and retailers are being notified 
by letter to stop distributing the products and to follow the recall 
instructions provided by the company. Questions about the recall 
can be directed to The Mentholatum Company at 877/636-2677, 
Monday through Friday, 9 am to 5 pm Eastern Time. FDA urges 
consumers and health care providers to report any adverse events 
or side effects related to the use of these products to FDA’s Med-
Watch Safety Information and Adverse Event Reporting Program. 
More information is available at www.fda.gov/Safety/Recalls/
ucm382076.htm.
FDA Provides Compounding Law 
Implementation Information
FDA has provided implementation information on Title I of 
the recently passed Drug Quality and Security Act – known as the 
Compounding Quality Act – through its website.
Of note, FDA specifies that compounding entities may register 
as an outsourcing facility, which, under certain conditions, may 
be exempt from the Federal Food, Drug, and Cosmetic Act’s 
(FD&C Act) approval and labeling requirements. Drugs produced 
by compounders that are not registered as outsourcing facilities 
must meet the conditions of Section 503A of the FD&C Act, which 
was amended by the new law, to qualify for certain exemptions.
The document adds, “If a compounded drug does not qualify 
for exemptions under either section 503A or 503B of the [FD&C 
Act], the compounded drug would be subject to all of the require-
ments of the [FD&C Act] that are applicable to drugs made by 
conventional manufacturers, including the new drug approval and 
adequate directions for use requirements.” FDA also notes it will 
provide additional information about how the agency will interpret 
certain provisions of Section 503A at a later date.
The implementation information may be viewed at www 
.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/ 
PharmacyCompounding/ucm375804.htm.
New e-LTP Fees Effective July 1, 2014
Supporting ongoing efforts to protect the integrity of its licensure 
transfer programs and to support the expansion of new technologies 
that are being implemented to enhance the program, the National 
Association of Boards of Pharmacy® (NABP®) is adjusting the 
fees for the Electronic Licensure Transfer Program® (e-LTP™).
Beginning July 1, 2014, the e-LTP fees will be adjusted as 
follows:
 ♦ The preliminary application and first state transfer fee will 
increase from $350 to $375
 ♦ Each additional state transfer will increase from $50 to $75
 ♦ Change of states will increase from $50 to $75
 ♦ Time extensions will increase from $50 to $75
The fees for e-LTP were last adjusted in 2010. More informa-
tion about e-LTP is available in the Programs section of the NABP 
website at www.nabp.net. Additional questions about the fee 
adjustment may be directed to Neal Watson, licensure programs 
manager, at 847/391-4406, or at nwatson@nabp.net.
Pharmacists & Technicians: 
Don't Miss Out on Valuable CPE Credit. 
Set Up Your NABP e-Profile and  
Register for CPE Monitor Today!
Continuing pharmacy education (CPE) providers who are accredited 
by the Accreditation Council for Pharmacy Education (ACPE) have 
integrated CPE Monitor® into their systems and are requiring pharmacists 
and pharmacy technicians to provide an NABP e-Profile ID number and 
date of birth (MMDD) in order to process ACPE-accredited CPE credit.
Visit www.MyCPEmonitor.net to set up your NABP e-Profile and 
register for CPE Monitor and avoid possible delays in your CPE reporting.
CPE Monitor is a national collaborative service from  
NABP, ACPE, and ACPE providers that will allow licensees  
to track their completed CPE credit electronically.
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education or administrative warnings. In other cases, nonresident 
pharmacies have been issued a Statement of Charges and Notice 
of Hearing, which initiates the formal disciplinary process. More 
information will be released as it becomes available.
As of April 22, 2014, Iowa has 685 nonresident pharmacies ac-
tively licensed to do business in Iowa.
Dispensing Products Containing 
Pseudoephedrine Without a Prescription
The Board frequently receives inquiries regarding over-the-
counter (OTC) sales of pseudoephedrine (PSE) products. Please 
note that pharmacies are not subject to single package limitations 
when selling OTC PSE products. Rule 657 IAC 10.32 provides all 
restrictions relating to PSE sales by pharmacies (emphasis added):
657 IAC—10.32 A product containing ephedrine, pseu-
doephedrine, or phenylpropanolamine, which substance 
is a Schedule V controlled substance and is not listed in 
another controlled substance schedule, may be dispensed 
or administered without a prescription by a pharmacist to 
a purchaser at retail pursuant to the conditions of this rule.
10.32(1) Who may dispense. Dispensing shall be by a licensed 
Iowa pharmacist or by a registered pharmacist-intern under 
the direct supervision of a pharmacist preceptor. This sub-
rule does not prohibit, after the pharmacist has fulfilled 
the professional and legal responsibilities set forth in this 
rule and has authorized the dispensing of the substance, 
the completion of the actual cash or credit transaction 
or the delivery of the substance by a nonpharmacist.
10.32(2) Packaging of nonliquid forms. A nonliquid form 
of a product containing ephedrine, pseudoephedrine, or 
phenylpropanolamine includes gel caps. Nonliquid forms 
of these products to be sold pursuant to this rule shall be 
packaged either in blister packaging with each blister con-
taining no more than two dosage units or, if blister packs 
are technically infeasible, in unit dose packets or pouches.
10.32(3) Frequency and quantity. Dispensing at retail 
to the same purchaser within any 30-day period shall be 
limited to products collectively containing no more than 
7,500 mg of ephedrine, pseudoephedrine, or phenylpro-
panolamine; dispensing at retail to the same purchaser 
within a single calendar day shall not exceed 3,600 mg.
10.32(4) Age of purchaser. The purchaser shall be at least 
18 years of age.
10.32(5) Identification. The pharmacist shall require every 
purchaser under this rule to present a current government-is-
sued photo identification, including proof of age when appro-
priate. The pharmacist shall be responsible for verifying that 
the name on the identification matches the name provided by 
the purchaser and that the photo image depicts the purchaser.
10.32(6) Record. Purchase records shall be recorded in 
the real-time electronic pseudoephedrine tracking system 
(PTS) established and administered by the governor’s of-
fice of drug control policy pursuant to 657 IAC—Chapter 
100 (the system commonly known as the NPLEx System).
Next Board Meeting
The Board plans to hold its next meeting at the Board office in 
Des Moines on June 30 to July 2, 2014. Administrative hearings 
and a closed session will be held on Monday, June 30, and Tuesday, 
July 1. The Board plans to meet in open session on Wednesday, July 
2. Please contact the Board office at 515/281-5944 to confirm dates, 
times, and location.
Board Mission
The Iowa Board of Pharmacy promotes, preserves, and protects 
the public health, safety, and welfare through the effective regula-
tion of the practice of pharmacy and the licensing of pharmacies, 
pharmacists, and others engaged in the sale, delivery, or distribution 
of prescription drugs and devices. Iowa Code §155A.2(1).
Board Website
Please visit the Board’s website at www.state.ia.us/ibpe/. 
Follow the Board on Facebook and Twitter
Continued from page 1
Facebook “Iowa Board of Pharmacy”
www.facebook.com/pages/Iowa-Board-of-
Pharmacy/223126781053672
Twitter “IABoardPharmacy”
http://twitter.com/#!/IABoardPharmacy
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